TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 7937663

Group type: EXPERIMENTAL
Intervention: multi‐modality therapy using tuberculin, oliphen plus prednisolone
Number of subjects: 82
Study: 3348612

Group type: EXPERIMENTAL
Intervention: Cefoperazone (3 g every 12 h) as a single agent
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Sulbactam (1.5 g every 12 h) as a single agent
Number of subjects: 14

Group type: COMPARATOR
Intervention: Cefoperazone and sulbactam combination (3/1.5 g)
Number of subjects: 14
Study: 29642080

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine (n = 23)
Number of subjects: 47

Group type: COMPARATOR
Intervention: Propofol (n = 24)
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Both drugs
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Number of subjects: 47
Study: 28126455

Group type: EXPERIMENTAL
Intervention: Telephone coaching intervention in conjunction with a health risk assessment (HRA)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Health risk assessment (HRA) alone
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Telephone coaching intervention
Number of subjects: 0
Study: 25920000

Group type: EXPERIMENTAL
Intervention: Low-dose alcohol (peak BrAC of 40mg/dL)
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Moderate-dose alcohol (peak BrAC of 65mg/dL)
Number of subjects: 62

Group type: COMPARATOR
Intervention: Placebo (peak BrAC of 0mg/dL)
Number of subjects: 62
Study: 24156469

Group type: EXPERIMENTAL
Intervention: Acupuncture plus usual care
Number of subjects: 40

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 40
Study: 21977941

Group type: EXPERIMENTAL
Intervention: Fluticasone furoate (FF) 400 mcg once daily in the evening
Number of subjects: 646

Group type: EXPERIMENTAL
Intervention: Fluticasone furoate (FF) 200 mcg twice daily
Number of subjects: 646

Group type: EXPERIMENTAL
Intervention: Fluticasone furoate (FF) 400 mcg once daily in the morning
Number of subjects: 646

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 646
Study: 19179834

Group type: EXPERIMENTAL
Intervention: +F
Number of subjects: 34

Group type: COMPARATOR
Intervention: ‐F
Number of subjects: 34
Study: 16530911

Group type: EXPERIMENTAL
Intervention: Homemade clove gel
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: Benzocaine 20% gel
Number of subjects: 73

Group type: COMPARATOR
Intervention: Placebo resembling clove
Number of subjects: 73

Group type: COMPARATOR
Intervention: Placebo resembling benzocaine
Number of subjects: 73
Study: 14603980

Group type: EXPERIMENTAL
Intervention: Herbal eye drops (itone eye drops)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Artificial tear
Number of subjects: 120

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study: 11014949

Group type: EXPERIMENTAL
Intervention: Vasopressin antagonist Atosiban (1‐deamino‐2‐D‐Tyr(OEt)‐4‐Thr‐8‐Orn‐oxytocin)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (women without primary dysmenorrhea)
Number of subjects: 0
Study: 8922872

Group type: EXPERIMENTAL
Intervention: Copper IUD
Number of subjects: 0

Group type: COMPARATOR
Intervention: Levonorgestrel-releasing IUS
Number of subjects: 0

Group type: COMPARATOR
Intervention: Levonorgestrel-releasing IUS (postabortal insertion)
Number of subjects: 0
Study: 1425870

Group type: EXPERIMENTAL
Intervention: Omeprazole (240 mg administered in three divided doses over 22 hours)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Normochlorhydria (no omeprazole treatment)
Number of subjects: 6
Study: 4085165

Group type: EXPERIMENTAL
Intervention: Active pulsed electromagnetic field therapy (PEMF)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Inactive pulsed electromagnetic field therapy (PEMF)
Number of subjects: 30
Study: 31293236

Group type: EXPERIMENTAL
Intervention: Culturally adapted children's weight management programme (6 sessions)
Number of subjects: 92

Group type: COMPARATOR
Intervention: Standard (unadapted) children's weight management programme
Number of subjects: 92
Study: 30512100

Group type: EXPERIMENTAL
Intervention: RAS inhibitor prescription at hospital discharge
Number of subjects: 15896

Group type: COMPARATOR
Intervention: No RAS inhibitor prescription
Number of subjects: 15896

Group type: EXPERIMENTAL
Intervention: RAS inhibitor prescription at hospital discharge (stratified by preserved LVEF)
Number of subjects: 15896

Group type: COMPARATOR
Intervention: No RAS inhibitor prescription (stratified by preserved LVEF)
Number of subjects: 15896

Group type: EXPERIMENTAL
Intervention: RAS inhibitor prescription at hospital discharge (KCCQ score analysis)
Number of subjects: 15896

Group type: COMPARATOR
Intervention: No RAS inhibitor prescription (KCCQ score analysis)
Number of subjects: 15896
Study: 26429068

Group type: EXPERIMENTAL
Intervention: High Fat (HF) meal
Number of subjects: 16

Group type: COMPARATOR
Intervention: High Carbohydrate (HCHO) meal
Number of subjects: 16
Study: 25353193

Group type: EXPERIMENTAL
Intervention: Wheelchair tilt and recline at 15, 25, and 35 degrees tilt with 10 and 30 degrees recline
Number of subjects: 13
Study: 22267715

Group type: EXPERIMENTAL
Intervention: Vero cell culture-derived influenza vaccine
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study: 19172131

Group type: EXPERIMENTAL
Intervention: Glutamine-enriched enteral nutrition (0.3 g x kg(‐1) x day(‐1))
Number of subjects: 102

Group type: COMPARATOR
Intervention: Control (isonitrogenous placebo supplementation - alanine)
Number of subjects: 102
Study: 17311977

Group type: EXPERIMENTAL
Intervention: Lactobacillus rhamnosus GG
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Bifidobacterium lactis Bb‐12
Number of subjects: 0
Study: 15939062

Group type: EXPERIMENTAL
Intervention: Flaxseed oil (FXO: high ALA, n = 21)
Number of subjects: 57

Group type: COMPARATOR
Intervention: Sunflower oil (SO: high linoleic acid, n = 17)
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Sunflower oil with fish-oil (SOF n = 19)
Number of subjects: 57
Study: 12563465

Group type: EXPERIMENTAL
Intervention: Early feeding after 24 hours post-operation
Number of subjects: 43

Group type: COMPARATOR
Intervention: Conventional feeding after ileus resolution
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 43
Study: 10591888

Group type: EXPERIMENTAL
Intervention: Flumazenil (1 mg/70 kg)
Number of subjects: 13

Group type: COMPARATOR
Intervention: Caffeine (300 mg/70 kg; active drug control)
Number of subjects: 13

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13
Study: 7854546

Group type: EXPERIMENTAL
Intervention: Scopolamine administration
Number of subjects: 6

Group type: COMPARATOR
Intervention: Placebo administration
Number of subjects: 6
Study: 1776257

Group type: EXPERIMENTAL
Intervention: verapamil
Number of subjects: 81

Group type: COMPARATOR
Intervention: nifedipine
Number of subjects: 81
Study: 6172922

Group type: EXPERIMENTAL
Intervention: Continuous lumbar epidural analgesia for up to 24 hours
Number of subjects: 38

Group type: COMPARATOR
Intervention: General anaesthesia with intermittent positive pressure ventilation
Number of subjects: 38
Study: 25646024

Group type: EXPERIMENTAL
Intervention: 5-day period of nap restriction (n=13)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Napping as usual (n=15)
Number of subjects: 28
Study: 29219073

Group type: EXPERIMENTAL
Intervention: Tummy time (30 min per day)
Number of subjects: 455

Group type: EXPERIMENTAL
Intervention: Kept restrained (no more than 1 h at a time)
Number of subjects: 455

Group type: EXPERIMENTAL
Intervention: Screen time (zero screen time)
Number of subjects: 455

Group type: EXPERIMENTAL
Intervention: Sleep (14-17 h for 0-3 month olds or 12-16 h for 4-11 month olds)
Number of subjects: 455

Group type: EXPERIMENTAL
Intervention: Combined guidelines (meeting all four guidelines)
Number of subjects: 455

Group type: COMPARATOR
Intervention: Screen time guideline by gender
Number of subjects: 455

Group type: COMPARATOR
Intervention: Combined guidelines by gender
Number of subjects: 455
Study: 25738849

Group type: EXPERIMENTAL
Intervention: 0.1% stabilized retinol
Number of subjects: 62

Group type: COMPARATOR
Intervention: Vehicle (control)
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Histochemical markers after retinol treatment
Number of subjects: 62

Group type: COMPARATOR
Intervention: Histochemical markers after vehicle treatment
Number of subjects: 62
Study: 23880355

Group type: EXPERIMENTAL
Intervention: Glucose intake
Number of subjects: 3496

Group type: EXPERIMENTAL
Intervention: Fructose intake
Number of subjects: 3496

Group type: EXPERIMENTAL
Intervention: Fructose intake (nutrient density method)
Number of subjects: 3496

Group type: EXPERIMENTAL
Intervention: Replacement of 5% energy intake from SFA with fructose
Number of subjects: 3496
Study: 22641251

Group type: EXPERIMENTAL
Intervention: Exercise training (3-month treadmill exercise training)
Number of subjects: 61

Group type: COMPARATOR
Intervention: Control group (N=33)
Number of subjects: 61
Study: 19494683

Group type: EXPERIMENTAL
Intervention: Approximal sealants
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Fluoride applications (including slow-release devices)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Measures to help remineralize demineralized tissue (including 3 different methods of delivering amorphous calcium phosphate)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Measures to help modify the biofilm (including ozone therapy and probiotics)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Measures to increase enamel resistance to demineralization (including laser treatment of enamel)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Novel 'hybrid' technique for treatment of primary molar caries (Hall technique)
Number of subjects: 0
Study: 18085105

Group type: EXPERIMENTAL
Intervention: Combined epidural and subarachnoid puncture using an introducer needle
Number of subjects: 224

Group type: EXPERIMENTAL
Intervention: Combined epidural and subarachnoid puncture without an introducer
Number of subjects: 224

Group type: EXPERIMENTAL
Intervention: Subarachnoid puncture with an introducer
Number of subjects: 224

Group type: COMPARATOR
Intervention: Subarachnoid puncture with an introducer to within a few millimeters of the dural sac
Number of subjects: 224
Study: 15193668

Group type: EXPERIMENTAL
Intervention: Descriptive and explanatory information (AUT‐D + E)
Number of subjects: 576

Group type: COMPARATOR
Intervention: Descriptive information alone (AUT‐D)
Number of subjects: 576

Group type: EXPERIMENTAL
Intervention: Combined information (AUT‐D + E)
Number of subjects: 576
Study: 11772963

Group type: EXPERIMENTAL
Intervention: Biennial screening with Hemoccult‐II
Number of subjects: 30967

Group type: COMPARATOR
Intervention: Control group (no screening)
Number of subjects: 30967

Group type: EXPERIMENTAL
Intervention: Non-responders (those who accepted the first screening but not subsequent ones)
Number of subjects: 30967
Study: 9834808

Group type: EXPERIMENTAL
Intervention: PCA with intravenous piritramide (group P-PCA)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Nurse-administered bolus injections of piritramide (group P-Bolus)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: PCA with subarachnoid bupivacaine (group B-PCA)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Nurse-administered bolus injections of bupivacaine (group B-Bolus)
Number of subjects: 120
Study: 8620675

Group type: EXPERIMENTAL
Intervention: Zileuton (600mg every 6 hours for 8 days)
Number of subjects: 20
Study: 2649324

Group type: EXPERIMENTAL
Intervention: NPH (Protaphane)
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: Lente (Monotard)
Number of subjects: 82
Study: 582533

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 31605294

Group type: EXPERIMENTAL
Intervention: Computer-assisted counseling
Number of subjects: 1036

Group type: COMPARATOR
Intervention: Standard counseling according to national guidelines
Number of subjects: 1036

Group type: EXPERIMENTAL
Intervention: On-demand counseling
Number of subjects: 1036
Study: 31860172

Group type: EXPERIMENTAL
Intervention: Positive affect intervention
Number of subjects: 110

Group type: COMPARATOR
Intervention: Attention-control condition
Number of subjects: 110
Study: 28276979

Group type: EXPERIMENTAL
Intervention: Restricted external stimulation (eyes closed + silence)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Non-restricted external stimulation (eyes open + ambient noise)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Presence of visual stimulation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Presence of auditory stimulation
Number of subjects: 0
Study: 26439112

Group type: EXPERIMENTAL
Intervention: FL training group (forced left instruction)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: NF training group (non-forced instruction)
Number of subjects: 26
Study: 23364953

Group type: EXPERIMENTAL
Intervention: Tenofovir disoproxil fumarate (TDF) 300 mg for 48 weeks followed by open-label TDF for an additional 192 weeks
Number of subjects: 641

Group type: COMPARATOR
Intervention: Adefovir dipivoxil (ADV) 10 mg for 48 weeks followed by open-label TDF for an additional 192 weeks
Number of subjects: 641

Group type: EXPERIMENTAL
Intervention: Tenofovir disoproxil fumarate (TDF)
Number of subjects: 641

Group type: COMPARATOR
Intervention: Adefovir dipivoxil (ADV)
Number of subjects: 641
Study: 21295383

Group type: EXPERIMENTAL
Intervention: Safflower oil (SAF) 8 g daily for 16 weeks
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Conjugated linoleic acid (CLA) 8 g daily for 16 weeks
Number of subjects: 55
Study: 18823072

Group type: EXPERIMENTAL
Intervention: Donepezil
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Escitalopram (internal standard)
Number of subjects: 0
Study: 17713595

Group type: EXPERIMENTAL
Intervention: Computer presentation of images with spider-like characteristics, n = 13
Number of subjects: 25

Group type: COMPARATOR
Intervention: Placebo group, n = 12
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Follow-up study after 6 months, n = 25 (combined treatment and placebo)
Number of subjects: 25
Study: 15887629

Group type: EXPERIMENTAL
Intervention: G 5.0 mg/M 400 mg
Number of subjects: 198

Group type: COMPARATOR
Intervention: G 2.5 mg/M 400 mg
Number of subjects: 198

Group type: EXPERIMENTAL
Intervention: G 5.0 mg/M 400 mg and G 2.5 mg/M 400 mg
Number of subjects: 198
Study: 10904994

Group type: EXPERIMENTAL
Intervention: Madden operation + tamoxifen 20 mg OD
Number of subjects: 121

Group type: EXPERIMENTAL
Intervention: Tumorectomy to disease free margins + tamoxifen 20 mg OD
Number of subjects: 121
Study: 9287060

Group type: EXPERIMENTAL
Intervention: Topical water and systemic doxycycline, 100 mg for 2 weeks
Number of subjects: 113

Group type: EXPERIMENTAL
Intervention: Topical 0.12% chlorhexidine (CHX) and systemic doxycycline, 100 mg for 2 weeks
Number of subjects: 113

Group type: EXPERIMENTAL
Intervention: Topical povidone‐iodine and systemic doxycycline, 100 mg for 2 weeks
Number of subjects: 113

Group type: EXPERIMENTAL
Intervention: Topical 0.12% CHX and placebo
Number of subjects: 113

Group type: COMPARATOR
Intervention: Topical water and placebo
Number of subjects: 113
Study: 8212751

Group type: EXPERIMENTAL
Intervention: Anticoagulation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 3607094

Group type: EXPERIMENTAL
Intervention: Dental splint and physiotherapy program
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Relaxation program (progressive muscle relaxation, biofeedback, stress management)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Minimal treatment program (transcutaneous electrical nerve stimulation)
Number of subjects: 21
Study: 30026154

Group type: EXPERIMENTAL
Intervention: Waiting after stent deployment
Number of subjects: 210

Group type: COMPARATOR
Intervention: Nonwaiting group
Number of subjects: 210
Study: 27154411

Group type: EXPERIMENTAL
Intervention: Diesel exhaust (DE) exposure prior to inoculation with live attenuated influenza virus (LAIV)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Diesel exhaust (DE) exposure
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: In vitro exposure to DE particles
Number of subjects: 0
Study: 23796162

Group type: EXPERIMENTAL
Intervention: Women Be Healthy 2 (modified intervention)
Number of subjects: 198

Group type: COMPARATOR
Intervention: Women Be Healthy (original intervention)
Number of subjects: 198

Group type: COMPARATOR
Intervention: No intervention
Number of subjects: 198
Study: 22594302

Group type: EXPERIMENTAL
Intervention: Low-to-moderate alcohol exposure in utero
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group (no alcohol exposure)
Number of subjects: 20
Study: 20920772

Group type: EXPERIMENTAL
Intervention: Recombinant human C1-inhibitor (rhC1INH) at 100 U/kg
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Recombinant human C1-inhibitor (rhC1INH) at 50 U/kg
Number of subjects: 70

Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 70
Study: 18756443

Group type: COMPARATOR
Intervention: Early activation (1-2 months post-implant use)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Late activation (1 year post-implant use)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (prior to initial implant activation)
Number of subjects: 0
Study: 11916780

Group type: EXPERIMENTAL
Intervention: Almitrine infusion at a rate of 8 microg x kg(‐1) x min(‐1) (Group A)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo (Group P)
Number of subjects: 16
Study: 9699223

Group type: EXPERIMENTAL
Intervention: Bioprim tablets (80 mg of trimethoprim/400 mg sulfamethoxazole)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Bactrim tablets (80 mg of trimethoprim/400 mg sulfamethoxazole)
Number of subjects: 12
Study: 7521788

Group type: EXPERIMENTAL
Intervention: 750 mg/m2 cyclophosphamide (CHOP)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: 1200 mg/m2 cyclophosphamide (CHOP)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: 1500 mg/m2 cyclophosphamide (CHOP)
Number of subjects: 27
Study: 2777436

Group type: EXPERIMENTAL
Intervention: Eccentric (ECC) torque
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Concentric (CONC) torque
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Concentric H/Q quotient
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: H/Q quotients not corrected for GET (CONC)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: H/Q quotients not corrected for GET (ECC)
Number of subjects: 20
Study: 4139900

Group type: EXPERIMENTAL
Intervention: Split course radiotherapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Modifications in treatment planning
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Large initial fractions and rest period
Number of subjects: 0
Study: 30980316

Group type: EXPERIMENTAL
Intervention: Angiotensin-converting enzyme inhibitors
Number of subjects: 0

Group type: COMPARATOR
Intervention: Censored surrogate outcome methods
Number of subjects: 0
Study: 27999170

Group type: EXPERIMENTAL
Intervention: Endobronchial valve treatment
Number of subjects: 31
Study: 25256248

Group type: EXPERIMENTAL
Intervention: Serum protein profiling using SELDI‐TOF MS
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Decision tree model of biomarkers
Number of subjects: 66
Study: 23571450

Group type: EXPERIMENTAL
Intervention: Transurethral plasma kinetic enucleation of prostate (TUPKEP)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Transurethral plasma kinetic resection of prostate (TUPKRP)
Number of subjects: 60
Study: 21161733

Group type: EXPERIMENTAL
Intervention: Shared decision-making intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 0
Study: 19442975

Group type: EXPERIMENTAL
Intervention: Lifestyle intervention
Number of subjects: 288

Group type: COMPARATOR
Intervention: Control (no intervention)
Number of subjects: 288

Group type: EXPERIMENTAL
Intervention: Lifestyle intervention (SDS-BMI reduction >0.5)
Number of subjects: 288
Study: 17116939

Group type: EXPERIMENTAL
Intervention: ATRA combined with three daunorubicin (DNR) plus AraC courses and a 2‐year maintenance regimen (AraC group)
Number of subjects: 340

Group type: COMPARATOR
Intervention: No AraC (no AraC group)
Number of subjects: 340
Study: 15361277

Group type: EXPERIMENTAL
Intervention: HICA (high iron and calcium)
Number of subjects: 12

Group type: COMPARATOR
Intervention: LI (low iron)
Number of subjects: 12
Study: 11289747

Group type: EXPERIMENTAL
Intervention: Radiotherapy as part of breast-conserving treatment (BCT) for DCIS
Number of subjects: 1010

Group type: COMPARATOR
Intervention: Breast-conserving treatment (BCT) for DCIS without specific mention of control
Number of subjects: 1010
Study: 9226731

Group type: EXPERIMENTAL
Intervention: Transcendental Meditation (TM) technique
Number of subjects: 0

Group type: COMPARATOR
Intervention: Stress education control condition
Number of subjects: 0
Study: 8431342

Group type: EXPERIMENTAL
Intervention: Alfentanil 20 micrograms kg‐1 and propofol 2.5 mg kg‐1
Number of subjects: 60

Group type: COMPARATOR
Intervention: Propofol 2.5 mg kg‐1
Number of subjects: 60
Study: 2441836

Group type: EXPERIMENTAL
Intervention: CABO (cisplatin, methotrexate, bleomycin, and vincristine)
Number of subjects: 185

Group type: COMPARATOR
Intervention: ABO (methotrexate, bleomycin, and vincristine)
Number of subjects: 185

Group type: EXPERIMENTAL
Intervention: CABO
Number of subjects: 185

Group type: COMPARATOR
Intervention: ABO
Number of subjects: 185
Study: 29671256

Group type: EXPERIMENTAL
Intervention: Growth Hormone (GH)
Number of subjects: 93

Group type: COMPARATOR
Intervention: Routine exogenous administration of estrogens
Number of subjects: 93
Study: 28267365

Group type: EXPERIMENTAL
Intervention: 2 mg E4
Number of subjects: 49

Group type: COMPARATOR
Intervention: 2 mg estradiol valerate (E2V)
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: 10, 20, or 40 mg E4
Number of subjects: 49
Study: 26259892

Group type: EXPERIMENTAL
Intervention: Synbiotic supplementation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard method with reduced calorie intake and increased physical activity
Number of subjects: 0
Study: 24011606

Group type: EXPERIMENTAL
Intervention: strategy-oriented neuropsychological rehabilitation (60-minute sessions once a week for thirteen consecutive weeks)
Number of subjects: 102

Group type: COMPARATOR
Intervention: control group (no intervention)
Number of subjects: 102
Study: 20214694

Group type: EXPERIMENTAL
Intervention: Outpatient (OP) treatment
Number of subjects: 59

Group type: COMPARATOR
Intervention: Inpatient (IP) treatment
Number of subjects: 59
Study: 19787599

Group type: EXPERIMENTAL
Intervention: dorzolamide/timolol (DTFC)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: latanoprost/timolol (LTFC)
Number of subjects: 30
Study: 16707588

Group type: EXPERIMENTAL
Intervention: Bortezomib
Number of subjects: 669

Group type: COMPARATOR
Intervention: Dexamethasone
Number of subjects: 669